An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts

• DOI: 10.3389/fgene.2022.1100317
• Publication Date: 2023-01-04T15:27:17Z
• Authors: Hao Deng; Dingshan Deng; Tiezheng Qi; Zhi Liu; Longxiang Wu; Junbin Yuan
• Keywords: 0301 basic medicine; 03 medical and health sciences; Genetics; bladder cancer; real-world cohort study; immunotherapy; prognosis; QH426-470; IFN-γ; 3. Good health

Bladder cancer (BLCA) is featured with high incidence and mortality. Whether the IFN-γ signaling could be used as an immunotherapy determinant for BLCA has not been fully confirmed. In this study, the transcriptome data and clinical information of BLCA samples were collected from The Cancer Genome Atlas (TCGA). Besides, four immunotherapy cohorts including IMvigor210 cohort, Gide cohort, Van Allen cohort, and Lauss cohort were collected. The Xiangya real-world cohort was used for independent validation. An IFN-γ-related signature was developed and validated in BLCA for predicting prognosis, mutation, tumor microenvironment status, and immunotherapy response. This is the first study focusing on the comprehensive evaluation of predictive values on the IFN-γ-related signature in BLCA. The potential clinical application of the IFN-γ-related signature was expected to be further validated with more prospective clinical cohorts.